1 |
Ketabforoush AHME, Chegini R, Barati S, Tahmasebi F, Moghisseh B, Joghataei MT, Faghihi F, Azedi F. Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series. Biomed Pharmacother 2023;160:114378. [PMID: 36774721 DOI: 10.1016/j.biopha.2023.114378] [Reference Citation Analysis]
|
2 |
Kawahata I, Fukunaga K. Protein Kinases and Neurodegenerative Diseases. IJMS 2023;24:5574. [DOI: 10.3390/ijms24065574] [Reference Citation Analysis]
|
3 |
Tsuchiya M, Kong W, Hiraoka Y, Haraguchi T, Ogawa H. TBK1 inhibitors enhance transfection efficiency by suppressing p62/SQSTM1 phosphorylation. Genes Cells 2023;28:68-77. [PMID: 36284367 DOI: 10.1111/gtc.12987] [Reference Citation Analysis]
|
4 |
Khatoon F, Haque S, Hashem A, Mahmoud A, Tashkandi H, Mathkor D, Harakeh S, Alghamdi B, Kumar V. Network-based approach for targeting human kinases commonly associated with amyotrophic lateral sclerosis and cancer. Front Mol Neurosci 2022;15:1023286. [PMID: 36590916 DOI: 10.3389/fnmol.2022.1023286] [Reference Citation Analysis]
|
5 |
Zhao J, Ren T, Li X, Guo T, Liu C, Wang X. Research Progress on the Role of Microglia Membrane Proteins or Receptors in Neuroinflammation and Degeneration. Front Cell Neurosci 2022;16:831977. [DOI: 10.3389/fncel.2022.831977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|